Iziphumo ezitsha zoLingo lwezonyango zoNyango lwezigulana ezingalaliswanga ngenxa ye-COVID-19

0 ububhanxa 3 | eTurboNews | eTN
Ibhalwe ngu Linda Hohnholz

I-Kintor Pharmaceutical Limited, inkampani ye-biotechnology yenqanaba lezonyango ephuhlisa iimolekyuli ezincinci kunye nonyango lwebhayoloji, ibhengeze ubhaliso kunye nedosi yesigulana sayo sokuqala e-China kulingo lwayo lwenqanaba lesi-III lwezonyango (NCT04869228) lweproxalutamide kunyango lwe-COVID-19. izigulana ezingalaliswayo kwiSibhedlele sesiThathu saBantu e-Shenzhen e-China nge-10 kaFebruwari, ngo-2022.

Ulingo lwesigaba sesi-III luphononongo olungacwangciswanga, oluyimfama kabini, olulawulwa yi-placebo, lwemimandla emininzi, oluyilelwe ukuvavanya ukusebenza nokhuseleko lweproxalutamide kwizigulana ezingalaliswayo zamadoda e-COVID-19. Ulingo lwesigaba sesi-III lubhalise phantse izigulane ezingama-200 kwiindawo ezikumazwe aquka iBrazil, iPhilippines kunye neMalaysia. I-China lelinye lamazwe aphambili athatha inxaxheba kolu lingo lwemimandla emininzi, olwavunywa yi-NMPA yaseTshayina ngoSeptemba 1, 2021. Iziza ezithatha inxaxheba kolu vavanyo e-China ziquka i-Beijing Ditan Hospital, i-China-Japan Friendship Hospital, i-Third. Isibhedlele saBantu sase-Shenzhen, iZiko leKlinikhi yezeMpilo yoLuntu yaseShanghai, iSibhedlele i-Hangzhou Xixi, iZiko lezeMpilo kaRhulumente laseChengdu kunye neSibhedlele seSihlanu sabantu baseSuzhou.

UGqr. Tong Youzhi, umseki, uSihlalo, kunye ne-CEO yeKintor Pharma, uthe, “Sithanda ukwenza umbulelo ongazenzisiyo kuMongameli uGqr. Hongzhou Lu kunye neqela lakhe kwiSibhedlele seSithathu saBantu saseShenzhen ngobhaliso lokuqala lwesigulana kunye nokufakwa kwedosi Ulingo lwezonyango lwe-proxalutamide lwesigaba sesi-Itu sokunyanga izigulane ezingalaliswayo ze-COVID-19 e-China, elinyathelo elibaluleke kakhulu kolu lingo lwezonyango lwemimandla emininzi. Siza kwenza zonke iinzame zokumema iisayithi ezininzi e-China ukuba zijoyine olu phononongo lubalulekileyo. Ngaphandle koko, ulingo lwezonyango lwezigulane ezilaliswayo ze-COVID-19 (NCT05009732) luqalise ukubhaliswa kwezigulana e-United States, e-Ukraine nakwiiPhilippines, kwaye ngoku liqhuba uvavanyo lwezigulane phambi kokubhaliswa kwiindawo e-China. Sikwaqhubela phambili inkqubo kwamanye amazwe athatha inxaxheba kulingo lwethu lwemimandla emininzi.”

INTO ONOKUYITHATHA KWELI NQAKU:

  • I-Kintor Pharmaceutical Limited, inkampani ye-biotechnology yenqanaba lezonyango ephuhlisa iimolekyuli ezincinci kunye nonyango lwebhayoloji, ibhengeze ubhaliso kunye nedosi yesigulana sayo sokuqala e-China kulingo lwayo lwenqanaba lesi-III lwezonyango (NCT04869228) lweproxalutamide kunyango lwe-COVID-19. izigulana ezingalaliswayo kwiSibhedlele sesiThathu saBantu e-Shenzhen e-China nge-10 kaFebruwari, ngo-2022.
  • UHongzhou Lu kunye neqela lakhe kwiSibhedlele sesiThathu saBantu saseShenzhen kubhaliso lwesigulana sokuqala kunye nethamo kwisigaba sesi-III solingo lwezonyango lwe-proxalutamide yokunyanga izigulane ezingalaliswayo ze-COVID-19 e-China, elinyathelo elibaluleke kakhulu kolu lingo lwezonyango lwengingqi ezininzi.
  • Ngaphandle koko, ulingo lwezonyango lwezigulane ezilaliswayo ze-COVID-19 (NCT05009732) luqalise ukubhaliswa kwezigulana e-United States, e-Ukraine nasePhilippines, kwaye ngoku liqhuba uvavanyo lwezigulane phambi kokubhaliswa kwiziza e-China.

<

Malunga nombhali

Linda Hohnholz

Umhleli oyintloko we eTurboNews esekwe kwi-eTN HQ.

Bhlisa
Yaziswe ngawo
guest
0 izimvo
Inline feedbacks
Jonga zonke izimvo
0
Ndingazithanda iingcinga zakho, nceda uphawule.x
Yabelana ku...